Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Manage your formulary budget
Anticipate generic drug launch
Find generic entry opportunities
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Treatment of erectile dysfunction|
|Abstract:||Erectile dysfunction, particularly impotence, priapism and Peyronie's disease is treated by the transurethral administration of a therapeutically effective agent. The agents are administered to the urethra by means of a penile insert (1) having a rapidly releasing coating (4) containing the agent on its exterior surface or by means of an inserter (27) carrying an agent containing dose of agent (31) which can be displaced into the urethra.|
|Inventor(s):||Place; Virgil A. (Kawaihae, HI), Gale; Robert M. (Los Altos, CA), Berggren; Randall G. (Livermore, CA)|
|Assignee:||Vivus, Inc. (Mountain View, CA)|
1. A dosage form for treating an erectile dysfunction comprising a shaft sized to be received within the male urethra and a composition retained within said shaft comprising an
effective amount of a vasoactive prostaglandin and at least one dispersant.
2. The dosage form of claim 1 wherein said composition weighs not more than about 50 mg.
3. The dosage form of claim 2 wherein dysfunction is impotence and said agent consists of a mixture of from about 10-1000 .mu.g of alprostadil and 50-1000 .mu.g of prazosin.
4. The dosage form of claim 1 wherein said composition comprises a urethral permeation enhancer for said agent.
5. The dosage form of claim 1 wherein said agent comprises one or more vasodilators in addition to said vasoactive prostaglandin.
6. The dosage form of claim 1 wherein said vasoactive prostaglandin is prostaglandin E.sub.1.
7. The dosage form of claim 1 wherein said vasoactive prostaglandin in prostaglandin E.sub.2.
8. The dosage form of claim 1 wherein said dispersant is selected from the group consisting of pharmaceutically acceptable materials which dissolve, melt or bioerode within the urethra to release the agent.
9. The dosage form of claim 5 wherein said vasodilators are selected from the group consisting of nitrates, long and short acting .alpha.-blockers, calcium blockers, ergot alkaloids, chlorpromazine, haloperidol, yohimbine, vasoactive intestinal peptides, dopamine agonists, opioid antagonists and mixtures thereof.
10. The dosage form of claim 1 wherein said vasodilator is an .alpha.-blocker.
11. The dosage form of claim 5 wherein said agent comprises about 10-2000 .mu.g of a vasoactive prostaglandin and at least one vasodilator selected from the group consisting of about 1-50 mg of papaverine, about 1-10 mg of phentolamine, about 50-2000 .mu.g of prazosin, about 50-2000 .mu.g of doxazosin about 50-2000 .mu.g of terazosin and mixtures thereof.
12. The dosage form of claim 11 wherein said agent comprises about 10-2000 .mu.g of a vasoactive prostaglandin.
13. The dosage form of claim 1 wherein said dispersant is selected from the group consisting of polyethylene glycol, propylene glycol, glycerine, polyvinyl pyrrolidine, polyvinyl alcohol, hydroxy alkyl celluloses, and cyclodextrins.
14. The dosage form of claim 1 wherein said dispersant comprises polyethylene glycol.
15. The dosage form of claim 1 wherein said dispersant comprises a cyclodextrin.
16. The dosage form of claim 12 wherein said vasoactive prostaglandin is selected from the group consisting of natural and synthetic prostaglandins, prostaglandin E.sub.1, alprostadil, misoprostol, enprostil, prostaglandin E.sub.2, and analogs thereof.
17. The dosage form of claim 11 wherein said agent consists essentially of alprostadil and prazosin.
18. The dosage form of claims 1 wherein said composition is present in an amount less than about 100 mg.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.